XL 999

Drug Profile

XL 999

Alternative Names: EXEL-0999; XL-999

Latest Information Update: 05 Oct 2010

Price : $50

At a glance

  • Originator Exelixis
  • Developer Exelixis; Symphony Capital Partners
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma

Most Recent Events

  • 11 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
  • 07 Nov 2006 Clinical data from a media release have been added to the adverse events section
  • 07 Nov 2006 Exelixis has suspended enrolment of new patients in a phase II clinical development programme for XL 999 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top